BRET-based bioSens-All® technology unleashing the full potential of GPCR drug discovery
GPCR
RTK
Continuously investing in our BRET-based biosensor technology, allowing to get powerful new insights on the functional pharmacology of native and variant transmembrane receptors to develop tailored, safer, and more efficacious therapeutics.
Specifically, we use a unique and proprietary set of biosensors, without tagging the receptors, to better understand the proximal signal transduction pathways of G protein coupled receptors (GPCRs), and Receptor Tyrosine Kinases (RTKs). We continue to expand the application of the technology to other transmembrane receptors such as Immune Checkpoint Receptors.
